T. Rowe Price Associates’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $202K | Buy |
17,864
+1,041
| +6% | +$11.8K | ﹤0.01% | 2708 |
|
|
2025
Q1 | $195K | Buy |
16,823
+2,984
| +22% | +$34.6K | ﹤0.01% | 2649 |
|
|
2024
Q4 | $118K | Buy |
13,839
+722
| +6% | +$6.16K | ﹤0.01% | 2795 |
|
|
2024
Q3 | $152K | Sell |
13,117
-12,235
| -48% | -$142K | ﹤0.01% | 2741 |
|
|
2024
Q2 | $299K | Buy |
25,352
+3,210
| +14% | +$37.9K | ﹤0.01% | 2412 |
|
|
2024
Q1 | $263K | Buy |
22,142
+944
| +4% | +$11.2K | ﹤0.01% | 2496 |
|
|
2023
Q4 | $260K | Buy |
21,198
+2,237
| +12% | +$27.4K | ﹤0.01% | 2435 |
|
|
2023
Q3 | $183K | Sell |
18,961
-13,555
| -42% | -$131K | ﹤0.01% | 2528 |
|
|
2023
Q2 | $293K | Sell |
32,516
-4,455
| -12% | -$40.1K | ﹤0.01% | 2368 |
|
|
2023
Q1 | $291K | Buy |
36,971
+92
| +0.2% | +$724 | ﹤0.01% | 2354 |
|
|
2022
Q4 | $249K | Buy |
36,879
+9,933
| +37% | +$67.1K | ﹤0.01% | 2447 |
|
|
2022
Q3 | $391K | Buy |
26,946
+5,947
| +28% | +$86.3K | ﹤0.01% | 2249 |
|
|
2022
Q2 | $207K | Buy |
20,999
+2,672
| +15% | +$26.3K | ﹤0.01% | 2581 |
|
|
2022
Q1 | $270K | Buy |
18,327
+3,666
| +25% | +$54K | ﹤0.01% | 2581 |
|
|
2021
Q4 | $194K | Buy |
+14,661
| New | +$194K | ﹤0.01% | 2764 |
|
|
2016
Q3 | – | Sell |
-191,993
| Closed | -$1.78M | – | 2542 |
|
|
2016
Q2 | $1.78M | Hold |
191,993
| – | – | ﹤0.01% | 1546 |
|
|
2016
Q1 | $1.73M | Buy |
191,993
+207
| +0.1% | +$1.86K | ﹤0.01% | 1553 |
|
|
2015
Q4 | $9.72M | Sell |
191,786
-6,757
| -3% | -$342K | ﹤0.01% | 1289 |
|
|
2015
Q3 | $9.92M | Sell |
198,543
-1,693
| -0.8% | -$84.6K | ﹤0.01% | 1306 |
|
|
2015
Q2 | $20M | Buy |
+200,236
| New | +$20M | ﹤0.01% | 1138 |
|